AGENDA
AGENDA
The APP hosts the following on site sessions, that will be also available on “live streamingâ€. Have a look at the APP Sessions Schedule:
Friday February 21 from 12.30 to 13.30 (CET)
Saturday February 22 from 13.00 to 13.45 (CET)
LIVE STREAMING
SESSION 1
followed by Q&A
Â
Speakers: Jennifer Pollock (UK) – Pierre-Régis Burgel (France)
Summary from EBROW sessions:
- Key messages on Phenotypes and Endotypes of Exacerbations
- Relevant updates on Bronchiectasis and NTM Treatment
LIVE STREAMING SESSION 2 followed by Q&A
Speakers: Mattia Nigro (Italy) – Michal Shteinberg (Israel)
Interesting sum up of the 3 BATTLES presented during EBROW:
- PSEUDOMONAS ERADICATION
- CFTR1 MODULATORS & BRONCHIECTASIS
- ICS2 IN BRONCHIECTASIS
1Cystic Fibrosis Transmembrane Conductance Regulator
2Inhaled Corticosteroids
Saturday February 22 from 16.00 to 18.30 (CET)
Open to the Public Conference “Dialogue on Bronchiectasisâ€
This session aims to raise awareness of Bronchiectasis plus any associated medical conditions,
and the impact of this disease on patients, families and caregivers
16:00 – 16:10 (CET)
Welcome & introduction
Pierre-Régis Burgel (France), Francesco Blasi (Italy), James D. Chalmers (UK)
16:10 – 16:30 (CET)
The burden of disease from Bronchiectasis
Alan Timothy (UK)
16:30 – 16:50 (CET)
The European lesson: what is needed for a correct “prise en charge�
Marlène Murris (France), Stefano Aliberti (Italy)
16:50 – 17:10 (CET)
The needs of patients and caregivers
Justine Hamaïde (France) in cooperation with MNT Mon Poumon Mon Air
17:10 – 18:10 (CET)
Round Table
Building a network in bronchiectasis: the rare diseases implication from a French to a European perspective
Introduced by Pierre-Régis Burgel
Chairs: Pierre-R̩gis Burgel (France), Francesco Blasi (Italy) РJames D. Chalmers (UK)
Discussants: Bernard Maitre (France), Marlène Murris (France), Thierry Nouvel (CF Europe, France), Jeanette Boyd (ELF, UK)
18:10 – 18:30 (CET)
Conclusion
Pierre-Régis Burgel (France), Francesco Blasi (Italy), James D. Chalmers (UK)
The Association and Patient Programme has been made possible, thanks to the independent unrestricted support grant from:
